Skip to main content
. 2022 Jun 30;34(3):238–255. doi: 10.21147/j.issn.1000-9604.2022.03.05

Table 2. Commonly used neoadjuvant/conversion chemotherapy regimens for resectable or borderline resectable pancreatic cancer.

Regimen Detailed protocol
ECOG PS, Eastern Cooperative Oncology Group performance status; 5-FU, 5-fluorouracil.
Gemcitabine + albumin-bound paclitaxel Albumin-bound paclitaxel 125 mg/m2 ivgtt, d 1, 8
Gemcitabine 1,000 mg/m2 ivgtt, d 1, 8
Repeat every 3 weeks
FOLFIRINOX (only for patients with ECOG PS
score 0−1) 		Oxaliplatin 85 mg/m2 ivgtt, d 1
Irinotecan 180 mg/m2 ivgtt, d 1
Calcium folinate 400 mg/m2 ivgtt, d 1
5-FU 400 mg/m2 bolus d 1
Followed by 5-FU 2,400 mg/m2 continuous infusion over 46 h
Repeat every 2 weeks
mFOLFIRINOX (only for patients with ECOG PS score 0−1) Oxaliplatin 85 mg/m2 ivgtt, d 1
Irinotecan 150 mg/m2 ivgtt, d 1
Calcium folinate 400 mg/m2 ivgtt, d 1
5-FU 2,400 mg/m2 continuous infusion over 46 h
Repeat every 2 weeks